Equities research analysts predict that Davita Inc (NYSE:DVA) will report earnings of $1.66 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Davita’s earnings, with estimates ranging from $1.42 to $1.75. Davita reported earnings of $0.90 per share during the same quarter last year, which would indicate a positive year over year growth rate of 84.4%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, February 12th.
According to Zacks, analysts expect that Davita will report full year earnings of $5.31 per share for the current fiscal year, with EPS estimates ranging from $5.24 to $5.38. For the next financial year, analysts forecast that the company will report earnings of $5.56 per share, with EPS estimates ranging from $5.42 to $5.87. Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Davita.
Davita (NYSE:DVA) last released its quarterly earnings data on Tuesday, November 5th. The company reported $1.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.24 by $0.29. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.85 billion. Davita had a return on equity of 19.95% and a net margin of 3.68%. Davita’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter last year, the business posted $0.56 EPS.
A number of analysts have recently commented on DVA shares. Raymond James lowered Davita from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. Wolfe Research downgraded Davita from an “outperform” rating to a “market perform” rating and set a $57.00 price objective for the company. in a research note on Friday, October 25th. SunTrust Banks raised their price objective on shares of Davita to $72.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. UBS Group cut their target price on shares of Davita from $61.00 to $60.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Finally, ValuEngine lowered shares of Davita from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $65.00.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Flinton Capital Management LLC increased its stake in shares of Davita by 3.3% in the second quarter. Flinton Capital Management LLC now owns 187,884 shares of the company’s stock valued at $10,571,000 after buying an additional 6,052 shares during the period. Sciencast Management LP bought a new position in shares of Davita during the third quarter worth about $1,017,000. Wedge Capital Management L L P NC raised its position in shares of Davita by 28.8% during the second quarter. Wedge Capital Management L L P NC now owns 37,691 shares of the company’s stock worth $2,120,000 after acquiring an additional 8,434 shares during the last quarter. Tibra Equities Europe Ltd acquired a new position in shares of Davita in the third quarter worth approximately $1,141,000. Finally, Bank of Hawaii acquired a new position in shares of Davita in the third quarter worth approximately $430,000. 94.41% of the stock is currently owned by hedge funds and other institutional investors.
DVA traded up $0.19 on Friday, reaching $72.70. The stock had a trading volume of 1,821,749 shares, compared to its average volume of 2,078,820. The company has a current ratio of 1.81, a quick ratio of 1.77 and a debt-to-equity ratio of 4.26. The company has a market capitalization of $9.43 billion, a price-to-earnings ratio of 20.36, a price-to-earnings-growth ratio of 0.59 and a beta of 1.67. Davita has a fifty-two week low of $43.40 and a fifty-two week high of $73.50. The firm has a 50-day moving average of $66.47 and a 200-day moving average of $58.15.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.